During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, MBA, FACP, FCCP, discussed the role of larotrectinib in a patient with NTRK fusion–positive cancer.
Therapeutic Options for NTRK-Mutated Thyroid Cancer
Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.
Krzysztof J. Misiukiewicz, MD, discusses sequencing of treatments in patients with NTRK-positive thyroid cancer.
Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.